Staphylococcus aureus bloodstream infections in Latin America: results of a multinational prospective cohort study

Background:Substantial heterogeneity in the epidemiology and management ofStaphylococcus aureusbacter-aemia (SAB) occurs in Latin America. We conducted a prospective cohort study in 24 hospitals from nine LatinAmerican countries.Objectives:To assess the clinical impact of SAB in Latin America.Patien...

Full description

Autores:
Seas, Carlos
Garcia, Coralith
Costa Salles, Mauro José
Labarca, Jaime A.
Luna, Carlos Marcelo
Alvarez Moreno, Carlos Arturo
Mejía-Villatoro, Carlos Rodolfo
Zurita, Jeannete
Guzmán-Blanco, Manuel
Rodríguez-Noriega, Eduardo
Reyes, Jinnethe
Arias, César A.
Ćarcamo, César Paul
Gotuzzo, Eduardo H.
Bruno, Didier
Efrón, Ernesto D.
del Castillo, Marcelo
Dei, Sanatorio Mater
Guimarães, Thaís
Ceballos, María Elena
Domínguez, Isabel
Riedel, Gisela
Valderrama, Sandra
Gualtero, Sandra Milena
Saavedra, Carlos Humberto
Tello, Betzabé
Guerrero, Fausto
Silvestre, María Mónica
Morfin-Otero, Rayo
Alcalde, Fray Antonio
Hidalgo, José A.
Hercilla, Luis
Silva, Marisela
Guzmán, Alfonso José
Tipo de recurso:
Article of journal
Fecha de publicación:
2017
Institución:
Universidad El Bosque
Repositorio:
Repositorio U. El Bosque
Idioma:
eng
OAI Identifier:
oai:repositorio.unbosque.edu.co:20.500.12495/3193
Acceso en línea:
http://hdl.handle.net/20.500.12495/3193
https://doi.org/10.1093/jac/dkx350
https://repositorio.unbosque.edu.co
Palabra clave:
Staphylococcus aureus
Estudios de cohortes
Mortalidad
Rights
openAccess
License
Acceso abierto
Description
Summary:Background:Substantial heterogeneity in the epidemiology and management ofStaphylococcus aureusbacter-aemia (SAB) occurs in Latin America. We conducted a prospective cohort study in 24 hospitals from nine LatinAmerican countries.Objectives:To assess the clinical impact of SAB in Latin America.Patients and methods:We evaluated differences in the 30 day attributable mortality among patients with SABdue to MRSA compared with MSSA involving 84 days of follow-up. Adjusted relative risks were calculated using ageneralized linear model.Results:A total of 1030 patients were included. MRSA accounted for 44.7% of cases with a heterogeneous geo-graphical distribution. MRSA infection was associated with higher 30 day attributable mortality [25% (78 of 312)versus 13.2% (48 of 363), adjusted RR: 1.94, 95% CI: 1.38–2.73,P,0.001] compared with MSSA in the multivari-able analysis based on investigators’ assessment, but not in a per-protocol analysis [13% (35 of 270) versus8.1% (28 of 347), adjusted RR: 1.10, 95% CI: 0.75–1.60,P"0.616] or in a sensitivity analysis using 30 day all-cause mortality [36% (132 of 367) versus 27.8% (123 of 442), adjusted RR: 1.09, 95% CI: 0.96–1.23,P"0.179].MRSA infection was not associated with increased length of hospital stay. Only 49% of MSSA bloodstream infec-tions (BSI) received treatment withb-lactams, but appropriate definitive treatment was not associated withlower mortality (adjusted RR: 0.93, 95% CI: 0.70–1.23,P"0.602).Conclusions:MRSA-BSIs in Latin America are not associated with higher 30 day mortality or longer length ofstay compared with MSSA. Management of MSSA-BSIs was not optimal, but appropriate definitive therapy didnot appear to influence mortality